Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agile Therapeutics, Inc. - Common Stock (NQ:AGRX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agile Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024
Via ACCESSWIRE
Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024
Agile Therapeutics, Inc. (NASDAQ: AGRX), the commercial-stage women’s healthcare company, posted a 122% increase in third-quarter revenue year-over-year, driven by strong demand for TwirlaⓇ... 
Via Benzinga
Why Shares of Agile Therapeutics Jumped This Week
The women's healthcare company got an analyst upgrade. 
Via The Motley Fool
Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023
From Agile Therapeutics, Inc.
Via GlobeNewswire
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics (NASDAQ: AGRX) Upgraded To “Buy” Rating By Analysts At Maxim Group
Via ACCESSWIRE
Agile Therapeutics (NASDAQ: AGRX) Upgraded To "Buy" Rating By Analysts At Maxim Group
Maxim Group, a major investment bank, conducts and publishes stock analysis through its Equity Research team. The team has a strong reputation in the industry; a host of major firms use its research.... 
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Agile Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2023
Via Benzinga
Agile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter
Via ACCESSWIRE
Agile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter
On August 9, Agile Therapeutics (NASDAQ: AGRX) released its second-quarter financial results, showing significant growth in revenue from its innovative weekly bi 
Via Benzinga
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
Live Conference Call and Webcast at 8:30 a.m. ET 
From Agile Therapeutics, Inc.
Via GlobeNewswire
This Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions of Women Thanks to a Partnership With Afaxys
Via ACCESSWIRE
Agile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of Women
Via ACCESSWIRE
This Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions Of Women Thanks To A Partnership With Afaxys
Agile Therapeutics, Inc.’s (NASDAQ: AGRX) partnership with Afaxys Pharma is expected to play a key role in propelling the women’ 
Via Benzinga
Agile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of Women
This month, Agile Therapeutics, Inc. (NASDAQ: AGRX) announced partnerships with FPA Women’s Health and 
Via Benzinga
Agile Sees Renewed Hope For Even Broader Adoption Of Its Weekly Birth Control Patch After Biden’s Latest Executive Order Expanding Contraceptive Coverage
Via ACCESSWIRE
Agile Sees Renewed Hope For Even Broader Adoption Of Its Weekly Birth Control Patch After Biden's Latest Executive Order Expanding Contraceptive Coverage
In June, President Biden issued an Executive Order on Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services. 
Via Benzinga
H.C. Wainwright Reiterates Buy Rating For Agile Therapeutics (NASDAQ: AGRX), Citing Growing Demand For Twirla, A Weekly Low Dose Birth Control Patch
Via ACCESSWIRE
This Women's Healthcare Company Raised $7.5 Million In A Public Offering And Says It's Targeting $25 To $30 Million Net Revenue By End Of 2023
Via ACCESSWIRE
Why Tattooed Chef Are Trading Lower By 47%; Here Are 20 Stocks Moving Premarket
Gainers Micromobility.com Inc. (NASDAQ: MCOM) shares surged 60% to $0.18 in pre-market trading. micromobility.com recently reported a strategic realignment to strengthen its financial position and... 
Via Benzinga
Agile Therapeutics Expects Its Innovative Once-A-Week Birth Control Patch To Drive Revenues Of $25-30 Million In 2023 - What Is The Hype All About?
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS